Editorial Changes—Report No. 8

1 July 2019–31 December 2019

1. In preparing compilations for registration during the above period, First Parliamentary Counsel made the following editorial changes under the *Legislation Act 2003*.
2. The summary of editorial changes for the 68 compilations affected is as follows:

| Item | Kind of editorial change | Number |
| --- | --- | --- |
| 1 | Changes to grammar, syntax or the use of conjunctives or disjunctives | 4 |
| 2 | Changes to punctuation | 9 |
| 3 | Changes to spelling | 2 |
| 4 | Changes to typeface | 8 |
| 5 | Changes to the way of referring to or expressing a date | 1 |
| 6 | Changes to the way of referring to or expressing a measurement | 2 |
| 7 | Correct a typographical error | 8 |
| 8 | Give effect to the misdescribed amendments as intended | 35 |
| 9 | Removal of redundant text | 6 |
| 10 | Renumbering of provisions | 2 |
| 11 | Reordering of definitions | 20 |
| 12 | Show the effect of an amendment of the instrument | 9 |
| 13 | Updates to cross‑references | 3 |
| 14 | Updates to references of a law or a provision | 4 |

1. Please note that each instance of the power being used in a compilation is counted. This means that for a number of compilations the power has been used multiple times (for example, to correct typographical errors in different sections of the same compilation).
2. Complete details of each use of the power within a compilation appears below:

National Redress Scheme for Institutional Child Sexual Abuse Declaration 2018, Compilation No. 21, Registration Date: 24 December 2019 [F2019C00928]

**Paragraph 6(i)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

Schedule 1 item 3 of the *National Redress Scheme for Institutional Child Sexual Abuse Amendment (2019 Measures No. 12) Declaration 2019* instructs to omit “, a residential college of a university or a local council” and substitute “or a residential college of a university.” in paragraph 6(i).

This action results in two full stops at the end of paragraph 6(i).

This compilation was editorially changed to omit the redundant full stop.

**Schedule 1 (paragraph (ih) of table item 69)**

**Kind of editorial change**

Change to spelling

**Details of editorial change**

Schedule 1 item 15 of the *National Redress Scheme for Institutional Child Sexual Abuse Amendment (2019 Measures No. 12) Declaration 2019* inserted table items 63 to 70 after table item 62 of Schedule 1.

Paragraph (ih) of table item 69 in Schedule 1 refers to “Ukranian” rather than “Ukrainian”.

This compilation was editorially changed to omit the word “Ukranian” and substitute the word “Ukrainian” to correct the spelling.

MRCA Treatment Principles, Compilation No. 19, Registration Date: 23 December 2019 [F2019C00927]

**Paragraph 1.4.1 (Interpretation) definition of “Notes for General Practitioners”**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

Schedule 2 item 15 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* omits the definition of **“Notes for Local Medical Officers”** and substitutes the definition for **“Notes for General Practitioners”**.

In the newly substituted definition there are no double quotation marks around the term “**Notes for General Practitioners**”.

This compilation was editorially changed to insert the double quotation marks around the term “**Notes for General Practitioners**” in paragraph 1.4.1 (Interpretation) to correct the punctuation.

**Paragraph 1.4.1 (Interpretation) definition of “period of care” (paragraph (a))**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 paragraph 18(a) of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* provides as follows:

**18 Paragraph 1.4.1 (Interpretation) definition of “period of care”**

(a) omit the paragraph, substitute:

“(a) a *general practitioner*; or”; and

The instruction does not specify which paragraph is to be omitted.

This compilation was editorially changed to omit and substitute paragraph (a) of the definition **“period of care”** in paragraph 1.4.1 (Interpretation) to give effect to the misdescribed amendment as intended.

**Paragraph 1.4.1 (Interpretation) definition of “subsequent period of care”**

**Kind of editorial change**

Change to typeface

**Details of editorial change**

Schedule 2 item 22 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit and substitute the definition of **“subsequent period of care”** (including the Note)”.

In the newly substituted definition, “practitioner” (first occurring) is missing italics from the letter “r” (last occurring).

This compilation was editorially changed to italicise the letter “r” (last occurring) in “practitioner” (first occurring) in the definition of **“subsequent period of care”** in paragraph 1.4.1 (Interpretation).

**Paragraph 3.5.1(1)(h)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

Schedule 2 item 25 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* omits and substitutes paragraph 3.5.1(1)(h). The newly substituted paragraph ends with a full stop after the semicolon.

This compilation was editorially changed to omit the full stop at the end of paragraph 3.5.1(1)(h) to correct the punctuation.

**Paragraphs 6A.1 and 6A.9.5**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended and change to typeface

**Details of editorial change**

Schedule 2 paragraph 34(g) of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “The LMO” and substitute “The general practitioner” in Part 6A.

The words “The LMO” appear twice in paragraph 6A.1 and once in paragraph 6A.9.5 of Part 6A.

This compilation was editorially changed to omit the words “The LMO” and substitute “The general practitioner” in paragraphs 6A.1 and 6A.9.5 to give effect to the misdescribed amendments as intended.

In paragraph 6A.9.5 the words “general practitioner” are missing italics and are now inconsistent with the rest of those words in that paragraph.

This compilation was editorially changed to insert italics on the words “general practitioner” in paragraph 6A.9.5.

**Subparagraph 6A.4A.1(a)(iii)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 item 40 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “*LMOs*” and substitute “*general practitioners*”.

The word “*LMOs*” does not appear in subparagraph 6A.4A.1(a)(iii). However, the word “*LMO*s” does appear.

This compilation was editorially changed to omit the word “*LMO*s” and substitute “*general practitioners*” in subparagraph 6A.4A.1(a)(iii) to give effect to the misdescribed amendment as intended.

**Paragraph 6A.8.1**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 paragraph 34(d) of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “an *LMO*” (wherever occurring) and substitute “a *general practitioner*” in Part 6A.

The words “An *LMO*” appear in paragraph 6A.8.1.

This compilation was editorially changed to omit the words “An *LMO*” and substitute “A *general practitioner*” in paragraph 6A.8.1 to give effect to the misdescribed amendment as intended.

**Paragraph 7.3.3(a)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 item 47 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “a *Local Medical Officer* or *other GP*” and substitute “a *general practitioner*” in paragraph 7.3.3(a).

The words “a *Local Medical Officer* or *other GP*” do not appear in paragraph 7.3.3(a). However, the words “a *Local Medical Officer or other GP*” do appear.

This compilation was editorially changed to omit the words “a *Local Medical Officer or other GP*” and substitute “a *general practitioner*” in paragraph 7.3.3(a) to give effect to the misdescribed amendment as intended.

Offshore Petroleum and Greenhouse Gas Storage Act 2006, Compilation No. 43, Registration Date: 20 December 2019 [C2019C00336]

**Paragraph 8(2)(a), clauses 1 to 8 of Schedule 1, Schedule 2 and Schedule 7**

**Kind of editorial change**

Changes to the way of referring to or expressing a measurement and correct a typographical error

**Details of editorial change**

Paragraph 8(2)(a), clauses 1 to 8 of Schedule 1, Schedule 2 and Schedule 7 contain multiple references to latitude and longitude.

This compilation was editorially changed to omit all references to “South” and “East” contained in the expression of latitude and longitude and substitute “S” and “E” respectively to bring these references into line with legislative drafting practice.

This compilation was also editorially changed to update the expression of whole degrees of latitude to 2 numerals by inserting “0” at the beginning of each sequence of numbers, as required.

This compilation was also editorially changed to set solid these occurrences of latitude and longitude by omitting the space after the degree symbol, the space after the prime symbol and the space before the initial capital letter indicating south or east.

This compilation was also editorially changed to omit all occurrences of an apostrophe indicating minutes and double quotation marks indicating seconds and substituting the prime symbol and double prime symbol respectively to bring these references into line with legislative drafting practice.

Paragraph 1(a) of Schedule 2 contains the longitude measurement “148° 06’ 04.60 East”.

This compilation was editorially changed to insert the double prime symbol after the seconds measurement “04.60” in paragraph 1(a) of Schedule 2 to correct the typographical error.

Treatment Principles, Compilation No. 23, Registration Date: 12 December 2019 [F2019C00908]

**Paragraph 1.4.1 (Interpretation) definition of “subsequent period of care”**

**Kind of editorial change**

Change to typeface

**Details of editorial change**

Schedule 1 item 21 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit and substitute the definition of **“subsequent period of care”** (including the Note)”.

In the newly substituted definition, “practitioner” (first occurring) is missing italics from the letter “r” (last occurring).

This compilation was editorially changed to italicise the letter “r” (last occurring) in “practitioner” (first occurring) in the definition of **“subsequent period of care”** in paragraph 1.4.1 (Interpretation).

**Paragraphs 6A.1 and 6A.9.5**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 paragraph 34(g) of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “The LMO” and substitute “The *general practitioner*” in Part 6A.

The words “The LMO” appear twice in paragraph 6A.1 and once in paragraph 6A.9.5 of Part 6A.

This compilation was editorially changed to omit the words “The LMO” and substitute “The *general practitioner*” in paragraphs 6A.1 and 6A.9.5 to give effect to the misdescribed amendments as intended.

**Paragraph 6A.8.1**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 34(d) of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “an *LMO*” (wherever occurring) and substitute “a *general practitioner*” in Part 6A.

The words “An *LMO*” appear in paragraph 6A.8.1.

This compilation was editorially changed to omit the words “An *LMO*” and substitute “A *general practitioner*” in paragraph 6A.8.1 to give effect to the misdescribed amendment as intended.

**Paragraph 7.5.1**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 49 of the *Veterans’ Affairs (Treatment Principles – Local Medical Officer) Amendment Instrument 2019* instructs to omit “an *LMO*” and substitute “a *general practitioner*” in paragraphs 7.3A.6B and 7.5.1.

The words “an *LMO*” do not appear in paragraph 7.5.1. However, the words “an LMO” do appear.

This compilation was editorially changed to omit the words “an LMO” and substitute “a *general practitioner*” in paragraph 7.5.1 to give effect to the misdescribed amendment as intended.

Work Health and Safety Regulations 2011, Compilation No. 14, Registration Date: 10 December 2019 [F2019C00898]

**Subregulation 5(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definitions of ***asbestos removalist***, ***hazardous area***, ***hazardous chemical***, ***hazardous manual task***, ***person with management or control of a workplace***, ***personal protective equipment***, ***personnel and materials hoist*** and ***safety data sheet*** in subregulation 5(1) to the correct alphabetical positions.

Export Control (Prescribed Goods—General) Order 2005, Compilation No. 8, Registration Date: 22 November 2019 [F2019C00859]

**Paragraph 2.01(4)(f)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

Paragraph 2.01(4)(f) ends in a full stop despite being followed by paragraph 2.01(4)(g).

This compilation was editorially changed to omit the full stop at the end of the paragraph (f) and substitute a semicolon to bring it into line with legislative drafting practice.

AusCheck Regulations 2017, Compilation No. 5, Registration Date: 15 November 2019 [F2019C00833]

**Subsections 21J(2) and (3) (heading)**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

Schedule 1 item 23 of the *AusCheck Legislation Amendment (Major National Events) Regulations 2019* instructs to insert Division 5A after Division 5 of Part 2. The newly inserted headings for subsections 21J(2) and (3) refer to “*18 year of age*”.

This compilation was editorially changed to omit “*18 year of age*” and substitute “*18 years of age*” from the headings for subsections 21J(2) and (3) to correct the typographical error.

**Subsection 21J(3) (heading)**

**Kind of editorial change**

Removal of redundant text

**Details of editorial change**

Schedule 1 item 23 of the *AusCheck Legislation Amendment (Major National Events) Regulations 2019* instructs to insert Division 5A after Division 5 of Part 2. The newly inserted heading for subsection 21J(3) refers to “*Individuals who under*”.

This compilation was editorially changed to omit the redundant word “*who*” from the heading to subsection 21J(3).

Private Health Insurance (Prostheses) Rules (No. 3) 2019, Compilation No. 1, Registration Date: 15 November 2019 [F2019C00834]

**Schedule 1, Part 3 – Prostheses List – Part C, 08.18 – Cardiac Ablation, 08.18.01 - Cryoablation**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 4 of the *Private Health Insurance (Prostheses) Amendment Rules (No. 7) 2019* provides as follows:

4. Schedule 1, Part 1 – Prostheses List – Part C, 08.18 – Cardiac Ablation, following table item dealing with billing code MN240

Add the item and subheadings

**08.18.01 - Cryoablation**

**08.18.02.01 - Ablation Catheter**

**Medtronic Australasia Pty Ltd**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| MI301 | Arctic Front Advance Cardiac CryoAblation Catheter / Pro | A flexible, over-the-wire balloon catheter used to ablate cardiac tissue A flexible, over-the-wire balloon catheter used to ablate cardiac tissue | 23mm, 28mm | $5,100.00 | The prosthesis is only to be used in a surgical procedure described in item 38290 OR 38287 in Group T8 of the Health Insurance (General Medical Services Table) Regulations 2018, AND where the procedure is for the treatment of atrial fibrillation. |

There is no “Schedule 1, Part 1 – Prostheses List – Part C, 08.18 – Cardiac Ablation”. However, there is a “Schedule 1, Part 3 – Prostheses List – Part C, 08.18 – Cardiac Ablation”.

This compilation was editorially changed to insert the text of the amendment in Schedule 1, Part 3 – Prostheses List – Part C, 08.18 – Cardiac Ablation following the table item dealing with billing code MN240 to give effect to the misdescribed amendment as intended.

Australian Radiation Protection and Nuclear Safety Regulations 2018, Compilation No. 1, Registration Date: 14 November 2019 [F2019C00829]

**Paragraph 84(h)**

**Kind of editorial change**

Update to a reference of a law or a provision

**Details of editorial change**

This compilation was editorially changed to reflect a change in the way that Northern Territory laws are cited.

Health Insurance (Section 3C General Medical Services – Other Medical Practitioner) Determination 2018, Compilation No. 5, Registration Date: 14 November 2019 [F2019C00828]

**Schedule 1 (item 2483 in Subgroup 7 of Group A30)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 item 1 of the *Health Insurance (Section 3C – Other Medical Practitioner and Telehealth) Amendment (Australian Statistical Geography Standard) Determination 2019* provides as follows:

**1 Schedule 1 (item 2483 in Subgroup A7 of Group A30)**

Repeal the item, substitute:

|  |  |  |
| --- | --- | --- |
| 2483 | Professional attendance by video conference of more than 45 minutes in duration by a medical practitioner – each attendance | 87.10 |

The instruction refers to “Subgroup A7” rather than “Subgroup 7”.

This compilation was editorially changed to repeal and substitute item 2483 in Subgroup 7 of Group A30 in Schedule 1 to give effect to the misdescribed amendment as intended.

Offshore Petroleum and Greenhouse Gas Storage (Regulatory Levies) Act 2003, Compilation No. 16, Registration Date: 13 November 2019 [C2019C00322]

**Section 3**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***NOPSEMA inspector*** in section 3 to the correct alphabetical position.

Civil Aviation Safety Regulations 1998, Compilation No. 83, Registration Date: 12 November 2019 [F2019C00821]

**Regulation 202.463 (note to the definition of *model aircraft stage 2 application day*)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 16 of the *Civil Aviation Safety Amendment (Remotely Piloted Aircraft and Model Aircraft—Registration and Accreditation) Regulations (No. 2) 2019* provides as follows:

16 Regulation 202.463 (note to the definition of *model aircraft stage 2 application day*)

Omit “29 May 2020 (or a later day determined by the Director)”, substitute “30 May 2022” (or a later day).

The closing quotation mark around the substituted text should appear after “(or a later day)”.

This compilation was editorially changed to omit “29 May 2020 (or a later day determined by the Director)” and substitute “30 May 2022 (or a later day)” in regulation 202.463 (note to the definition of ***model aircraft stage 2 application day***) to give effect to the misdescribed amendment as intended.

Health Insurance (Extended Medicare Safety Net) Determination 2017, Compilation No. 2, Registration Date: 12 November 2019 [F2019C00818]

**Paragraph 4(6)(a)**

**Kind of editorial change**

Renumbering of provisions

**Details of editorial change**

Schedule 1 item 9 of the *Health Insurance (Extended Medicare Safety Net) Amendment (Eating Disorders Capping) Determination 2019* provides as follows:

9 Paragraph 4(6)(a)

Repeal the paragraph, substitute:

(b) subsections 10ACA(7A) and 10ADA(8A) apply to the items of the diagnostic imaging services table, and items in a determination made under subsection 3C(1) of the Act, listed in column 1 of the table below; and

Item 9 repeals paragraph 4(6)(a) and substitutes paragraph 4(6)(b). Paragraph 4(6)(b) already appears.

This compilation was editorially changed by renumbering the provision inserted by Schedule 1 item 9 as paragraph 4(6)(a).

National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010), Compilation No. 99, Registration Date: 11 November 2019 [F2019C00816]

**Schedule 1, entry for Adalimumab in each of the forms: Injection 20 mg in 0.4 mL pre-filled syringe; Injection 40 mg in 0.8 mL pre-filled syringe; and Injection 40 mg in 0.8 mL pre-filled pen**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 item 2 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) provides as follows:

**[2] Schedule 1, entry for Adalimumab in each of the forms: Injection 20 mg in 0.4 mL pre filled syringe; Injection 40 mg in 0.8 mL pre filled syringe; and Injection 40 mg in 0.8 mL pre filled pen**

*omit from the column headed “Circumstances” (all instances):* **C4464 C4465 C4491 C4500 C4546***substitute:* **C9384 C9417 C9423 C9424 C9425 C9426**

There is no entry in Schedule 1 for Adalimumab in each of the forms: Injection 20 mg in 0.4 mL pre filled syringe; Injection 40 mg in 0.8 mL pre filled syringe; and Injection 40 mg in 0.8 mL pre filled pen. However, there is an entry for Adalimumab in each of the forms: Injection 20 mg in 0.4 mL pre‑filled syringe; Injection 40 mg in 0.8 mL pre‑filled syringe; and Injection 40 mg in 0.8 mL pre‑filled pen. The instruction is missing hyphens between “pre” and “filled”.

This compilation was editorially changed to omit and substitute from the column headed “Circumstances” all instances of the circumstances codes from the amending item for Adalimumab in each of the forms: Injection 20 mg in 0.4 mL pre‑filled syringe; Injection 40 mg in 0.8 mL pre‑filled syringe; and Injection 40 mg in 0.8 mL pre‑filled pen in Schedule 1 to give effect to the misdescribed amendments as intended.

**Schedule 1, entry for Peginterferon alfa-2a in the form Injection 135 micrograms in 0.5 mL single use pre-filled syringe**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 item 31 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) provides as follows:

**[31] Schedule 1, entry for Peginterferon alfa-2a in the form Injection 135 micrograms in 0.5 mL single use pre filled syringe**

**(a)** *omit from the column headed “Circumstances”:* **C5016**

**(b)** *insert in numerical order in the column headed “Circumstances”:* **C9603**

There is no entry in Schedule 1 for Peginterferon alfa-2a in the form Injection 135 micrograms in 0.5 mL single use pre filled syringe. However, there is an entry for Peginterferon alfa-2a in the form Injection 135 micrograms in 0.5 mL single use pre-filled syringe. The instruction is missing a hyphen between “pre” and “filled”.

This compilation was editorially changed to omit “C5016” from, and insert “C9603” into, the column headed “Circumstances” in the entry for Peginterferon alfa-2a in the form Injection 135 micrograms in 0.5 mL single use pre-filled syringe in Schedule 1 to give effect to the misdescribed amendments as intended.

**Schedule 1, entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre-filled syringe *[Maximum Quantity: 4; Number of Repeats: 2]***

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 item 32 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) provides as follows:

**[32] Schedule 1, entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre filled syringe *[Maximum Quantity: 4; Number of Repeats: 2]***

**(a)** *omit from the column headed “Circumstances”:* **C5016**

**(b)** *insert in numerical order in the column headed “Circumstances”:* **C9603**

There is no entry in Schedule 1 for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre filled syringe *[Maximum Quantity: 4; Number of Repeats: 2]*. However, there is an entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre-filled syringe *[Maximum Quantity: 4; Number of Repeats: 2]*. The instruction is missing a hyphen between “pre” and “filled”.

This compilation was editorially changed to omit “C5016” from, and insert “C9603” into, the column headed “Circumstances” in the entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre-filled syringe *[Maximum Quantity: 4; Number of Repeats: 2]* in Schedule 1 to give effect to the misdescribed amendments as intended.

**Schedule 1, entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre-filled syringe *[Maximum Quantity: 8; Number of Repeats: 5]***

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 item 33 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) provides as follows:

**[33] Schedule 1, entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre filled syringe *[Maximum Quantity: 8; Number of Repeats: 5]***

**(a)** *omit from the column headed “Circumstances”:* **C5016**

**(b)** *insert in numerical order in the column headed “Circumstances”:* **C9603**

**(c)** *omit from the column headed “Purposes”:* **P5016**

**(d)** *insert in numerical order in the column headed “Purposes”:* **P9603**

There is no entry in Schedule 1 for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre filled syringe *[Maximum Quantity: 8; Number of Repeats: 5]*. However, there is an entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre-filled syringe *[Maximum Quantity: 8; Number of Repeats: 5]*. The instruction is missing a hyphen between “pre” and “filled”.

This compilation was editorially changed to omit “C5016” from, and insert “C9603” into, the column headed “Circumstances”, and to omit “P5016” from, and insert “P9603” into, the column headed “Purposes” in the entry for Peginterferon alfa-2a in the form Injection 180 micrograms in 0.5 mL single use pre-filled syringe *[Maximum Quantity: 8; Number of Repeats: 5]* in Schedule 1 to give effect to the misdescribed amendments as intended.

**Schedule 3, entry for Adalimumab**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 43 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) instructs to substitute the entry for Adalimumab in Schedule 3.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Adalimumab” in the column headed “Listed Drug” in Schedule 3.

**Schedule 3, entry for Clozapine**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 48(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) instructs to omit the entry for circumstances code C5001 of Clozapine in Schedule 3.

The text contained in the column headed “Circumstances and Purposes” does not exactly match the text to be omitted as outlined in Schedule 1 paragraph 48(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019).

This compilation was editorially changed to omit the entry for circumstances code C5001 of Clozapine in Schedule 3 to give effect to the misdescribed amendment as intended.

**Schedule 3, entry for Dornase alfa**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 50(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) instructs to omit the entry for circumstances code C5715 of Dornase alfa in Schedule 3.

The text contained in the column headed “Circumstances and Purposes” does not exactly match the text to be omitted as outlined in Schedule 1 paragraph 50(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019).

This compilation was editorially changed to omit the entry for circumstances code C5715 of Dornase alfa in Schedule 3 to give effect to the misdescribed amendment as intended.

**Schedule 3, entry for Etanercept**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 51 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) instructs to substitute the entry for Etanercept in Schedule 3.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Etanercept” in the column headed “Listed Drug” in Schedule 3.

**Schedule 3, entry for Rituximab**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 61 of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) instructs to substitute the entry for Rituximab in Schedule 3.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Rituximab” in the column headed “Listed Drug” in Schedule 3.

**Schedule 3, entry for Tocilizumab**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 63(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019) instructs to omit the entry for circumstances codes C4542 and C5977 of Tocilizumab in Schedule 3.

The text contained in the column headed “Circumstances and Purposes” does not exactly match the text to be omitted as outlined in Schedule 1 paragraph 63(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 78 of 2019).

This compilation was editorially changed to omit the entry for circumstances codes C4542 and C5977 of Tocilizumab in Schedule 3 to give effect to the misdescribed amendment as intended.

National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012), Compilation No. 84, Registration Date: 5 November 2019 [F2019C00802]

**Schedule 1, entry for Apomorphine in the form Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 paragraphs 17(a) and (b) of the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 9)* (PB 76 of 2019) provide as follows:

[17] Schedule 1, entry for Apomorphine in the form Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20

**(a)** omit from the column headed "Circumstances": C4860

**(b)** insert in numerical order in the column headed “Circumstances”: C9561

The instruction refers to “Apomorphine in the form Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20” rather than “Apomorphine in the form Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL”.

This compilation was editorially changed to omit “C4860” from, and insert “C9561” into, the column headed “Circumstances” in the entry for Apomorphine in the form Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL in Schedule 1 to give effect to the misdescribed amendments as intended.

**Schedule 4, Part 1, entry for Rituximab**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 214 of the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 9)* (PB 76 of 2019) instructs to substitute the entry for Rituximab in Schedule 4, Part 1.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Rituximab” in the column headed “Listed Drug” in Schedule 4, Part 1.

National Greenhouse and Energy Reporting Regulations 2008, Compilation No. 19, Registration Date: 31 October 2019 [F2019C00796]

**Regulation 1.03**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***engage in audit activity*** in regulation 1.03 to the correct alphabetical position.

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011), Compilation No. 91, Registration Date: 18 October 2019 [F2019C00778]

**Schedule 4, entry for Blinatumomab**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 29 of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 79 of 2019) instructs to substitute the entry for Blinatumomab in Schedule 4.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Blinatumomab” in the column headed “Listed Drug” in Schedule 4.

**Schedule 4, entry for Inotuzumab ozogamicin**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 30 of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 79 of 2019) instructs to substitute the entry for Inotuzumab ozogamicin in Schedule 4.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Inotuzumab ozogamicin” in the column headed “Listed Drug” in Schedule 4.

**Schedule 4, entry for Pertuzumab**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 31 of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 79 of 2019) instructs to substitute the entry for Pertuzumab in Schedule 4.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Pertuzumab” in the column headed “Listed Drug” in Schedule 4.

**Schedule 4, entry for Trastuzumab**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 33 of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 79 of 2019) instructs to substitute the entry for Trastuzumab in Schedule 4.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Trastuzumab” in the column headed “Listed Drug” in Schedule 4.

**Schedule 4, entry for Trastuzumab emtansine**

**Kind of editorial change**

Show the effect of an amendment of the instrument

**Details of editorial change**

Schedule 1 item 34 of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 9)* (PB 79 of 2019) instructs to substitute the entry for Trastuzumab emtansine in Schedule 4.

The substituted entry does not contain the drug name in the column headed “Listed Drug”.

This compilation was editorially changed to show the effect of an amendment of the instrument by inserting “Trastuzumab emtansine” in the column headed “Listed Drug” in Schedule 4.

Veterans’ Entitlements Act 1986, Compilation No. 156, Registration Date: 16 October 2019 [C2019C00311]

**Subclause 1(3) of Schedule 5**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***original component*** in subclause 1(3) of Schedule 5 to the correct alphabetical position.

Defence Service Homes Act 1918, Compilation No. 26, Registration Date: 9 October 2019 [C2019C00303]

**Subsection 6C(3)**

**Kind of editorial change**

Changes to typeface

**Details of editorial change**

This compilation was editorially changed to update two occurrences of the italicised words *ad valorem* to regular font.

Telecommunications (Interception and Access) Act 1979, Compilation No. 106, Registration Date: 4 October 2019 [C2019C00299]

**Subsection 5(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***main unexplained wealth provisions*** in subsection 5(1) to the correct alphabetical position.

Veterans’ Entitlements Act 1986, Compilation No. 155, Registration Date: 4 October 2019 [C2019C00300]

**Subpoint SCH6‑A1(2) (method statement 1, note 6)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

After “Note 6” of method statement 1 in subpoint SCH6‑A1(2) there is a full stop. The legislative drafting practice is to include a colon after the note number.

This compilation was editorially changed to omit the full stop and insert a colon after “Note 6” of method statement 1 in subpoint SCH6‑A1(2) to bring it into line with legislative drafting practice.

**Subpoint SCH6‑A1(6) (method statement 5, note 6)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

After “Note 6” of method statement 5 in subpoint SCH6‑A1(6) there is a full stop. The legislative drafting practice is to include a colon after the note number.

This compilation was editorially changed to omit the full stop and insert a colon after “Note 6” of method statement 5 in subpoint SCH6‑A1(6) to bring it into line with legislative drafting practice.

Customs Act 1901, Compilation No. 157, Registration Date: 2 October 2019 [C2019C00298]

**Section 145**

**Kind of editorial change**

Change to typeface

**Details of editorial change**

This compilation was editorially changed to update an occurrence of the italicised words *ad valorem* to regular font.

Private Health Insurance (Complying Product) Rules 2015, Compilation No. 22, Registration Date: 30 September 2019 [F2019C00737]

**Subrule 8A(3) (paragraph (a) of the definition of *patient contribution*)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 item 1 of the *Private Health Insurance Legislation Amendment (No. 3) Rules 2019* instructs to repeal and substitute subsection 8A(3) (paragraph (a) of the definition of ***patient contribution***).

Subsection 8A(3) does not appear. However, subrule 8A(3) does appear.

This compilation was editorially changed to repeal and substitute subrule 8A(3) (paragraph (a) of the definition of ***patient contribution***) and give effect to the misdescribed amendment as intended.

**Subrule 8A(3) (paragraph (b) of the definition of *patient contribution*)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 item 2 of the *Private Health Insurance Legislation Amendment (No. 3) Rules 2019* instructs to amend subsection 8A(3) (paragraph (b) of the definition of ***patient contribution***).

Subsection 8A(3) does not appear. However, subrule 8A(3) does appear.

This compilation was editorially changed to amend subrule 8A(3) (paragraph (b) of the definition of ***patient contribution***) and give effect to the misdescribed amendment as intended.

National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012), Compilation No. 83, Registration Date: 26 September 2019 [F2019C00723]

**Schedule 1, entry for Somatropin in the form Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 paragraphs 111(c) and (d) of the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 8)* (PB 66 of 2019) provide as follows:

[111] Schedule 1, entry for Somatropin in the form Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)

**(c)** omit from the column headed “Circumstances” for the brand “Omnitrope Surepal 10”: C8382

**(d)** insert in numerical order in the column headed “Circumstances” for the brand “Omnitrope Surepal 10”: C9257

The instruction refers to “Omnitrope Surepal 10” for the brand rather than “Omnitrope Surepal 5”.

This compilation was editorially changed to omit “C8382” from, and insert “C9257” into, the column headed “Circumstances” for the brand “Omnitrope Surepal 5” in the entry for Somatropin in the form Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative) in Schedule 1 to give effect to the misdescribed amendments as intended.

**Schedule 1, entry for Somatropin in the form Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 paragraphs 111(e) and (f) of the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 8)* (PB 66 of 2019)provide as follows:

[111] Schedule 1, entry for Somatropin in the form Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)

**(e)** omit from the column headed “Circumstances” for the brand “SciTropin A”: C8382

**(f)** insert in numerical order in the column headed “Circumstances” for the brand “SciTropin A”: C9257

The instruction refers to “SciTropin A” for the brand rather than “Scitropin A”.

This compilation was editorially changed to omit “C8382” from, and insert “C9257” into, the column headed “Circumstances” for the brand “Scitropin A” in the entry for Somatropin in the form Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative) in Schedule 1 to give effect to the misdescribed amendments as intended.

National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010), Compilation No. 79, Registration Date: 23 September 2019 [F2019C00716]

**Schedule 1, entry for Mirtazapine**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item [2] of the *National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 8)* (PB 74 of 2019) instructs as follows:

**[2]   Schedule 1, entry for Mirtazapine**

*omit:*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Tablet 15 mg (orally disintegrating) | Oral | Avanza SolTab | 30 | 3.85 | 8.27 |
|  | Tablet 30 mg (orally disintegrating) | Oral | Avanza SolTab | 30 | 5.13 | 9.55 |
|  | Tablet 45 mg (orally disintegrating) | Oral | Avanza SolTab | 30 | 7.72 | 12.14 |

However, there is more than one brand in each of the forms “Tablet 15 mg (orally disintegrating)”, “Tablet 30 mg (orally disintegrating)” and “Tablet 45 mg (orally disintegrating)”, which require the above information to remain in the columns headed “Form” and “Manner of Administration”.

This compilation was editorially changed to omit only the references to “Avanza SolTab” from the column headed “Brand” and the values specified for Avanza SolTab in the columns headed “Pricing Quantity/Pack Quantity”, “Determined Price $” and “Claimed Price $” to give effect to the misdescribed amendment as intended.

Passenger Movement Charge Collection Act 1978, Compilation No. 21, Registration Date: 23 September 2019 [C2019C00286]

**Subsection 13(1) and paragraph 13(2)(b)**

**Kind of editorial change**

Changes to typeface

**Details of editorial change**

This compilation was editorially changed to update two occurrences of the italicised words *prima facie* to regular font.

Income Tax Assessment Act 1936, Compilation No. 163, Registration Date: 19 September 2019 [C2019C00278]

**Subsection 170(9D)**

**Kind of editorial change**

Change to typeface

**Details of editorial change**

This compilation was editorially changed to update an occurrence of the italicised words *ab initio* to regular font.

Environment Protection and Biodiversity Conservation Act 1999, Compilation No. 53, Registration Date: 18 September 2019 [C2019C00275]

**Section 528**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***Director of Biosecurity*** in section 528 to the correct alphabetical position.

Income Tax Assessment Act 1997, Compilation No. 197, Registration Date: 12 September 2019 [C2019C00265]

**Paragraph 417‑75(b)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

Schedule 1 item 1 of the *Treasury Laws Amendment (Timor Sea Maritime Boundaries Treaty) Act 2019* instructs to insert Division 417 after Division 415. The newly inserted paragraph 417‑75(b) ends with a colon.

This compilation was editorially changed by removing the colon and inserting a semi‑colon at the end of paragraph 417‑75(b) to bring it into line with legislative drafting practice.

List of Exempt Native Specimens Instrument 2001, Compilation No. 355, Registration Date: 12 September 2019 [F2019C00699]

**Schedule 1, entry for Eastern Tuna and Billfish Fishery**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 of the *Amendment of List of Exempt Native Specimens – Commonwealth Eastern Tuna and Billfish Fishery and Commission for the Conservation of Antarctic Marine Living Resources Ross Sea Exploratory Toothfish Fishery, August 2019* provides as follows:

Under the heading Freshwater and Marine Animals delete from the list the following items and any associated notations:

|  |  |  |
| --- | --- | --- |
| **Taxon/Item** | **Common Name** | **Notation** |
| Specimens that are or are derived from fish or invertebrates, other than: specimens that belong to species listed under Part 13 of the EPBC Act, and specimens that belong to taxa listed under section 303CA of the EPBC Act (Australia’s CITES list) taken in the Eastern Tuna and Billfish Fishery, as defined in the Eastern Tuna and Billfish Fishery Management Plan 2010 in force under the Commonwealth *Fisheries Management Act 1991*, | Commonwealth Eastern Tuna and Billfish Fishery | * the specimen, or the fish or invertebrate from which it is derived, was taken lawfully; and * the specimens are included in the list until 22 August 2019. |

There is no entry under the heading Freshwater and Marine Animals for “Commonwealth Eastern Tuna and Billfish Fishery”. However, there is an entry under the heading Freshwater and Marine Animals for “Eastern Tuna and Billfish Fishery”.

This compilation was editorially changed to omit from under the the heading Freshwater and Marine Animals the entry for “Eastern Tuna and Billfish Fishery” to give effect to the misdescribed amendment as intended.

**Schedule 1, entry for Ross Sea Exploratory Toothfish Fishery**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 of the *Amendment of List of Exempt Native Specimens – Commonwealth Eastern Tuna and Billfish Fishery and Commission for the Conservation of Antarctic Marine Living Resources Ross Sea Exploratory Toothfish Fishery, August 2019* provides as follows:

Under the heading Freshwater and Marine Animals delete from the list the following items and any associated notations:

|  |  |  |  |
| --- | --- | --- | --- |
| **Taxon/Item** | **Common Name** | | **Notation** |
| Specimens that are or are derived from fish or invertebrates, other than: specimens that belong to species listed under Part 13 of the EPBC Act, and specimens that belong to taxa listed under section 303CA of the EPBC Act (Australia’s CITES list) taken by Australian flagged vessels authorised under permits issued under the *Commonwealth Fisheries Management Act 1991* to operate in the ‘Exploratory fishery for Dissostichus spp. in Subareas 88.1 and 88.2’ of the Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR) Convention Area (**Ross Sea exploratory toothfish fishery**) | | Ross Sea Exploratory Toothfish Fishery | * the specimen, or the fish or invertebrate from which it is derived, was taken lawfully, and * the specimens are included in the list until 31 October 2019. |

The text contained in the Taxon/Item, Common Name and Notation columns of the Schedule 1 entry for Ross Sea Exploratory Toothfish Fishery does not exactly match the text to be omitted as outlined in Schedule 1 of the *Amendment of List of Exempt Native Specimens – Commonwealth Eastern Tuna and Billfish Fishery and Commission for the Conservation of Antarctic Marine Living Resources Ross Sea Exploratory Toothfish Fishery, August 2019*.

This compilation was editorially changed to omit the Schedule 1 entry for Ross Sea Exploratory Toothfish Fishery and give effect to the misdescribed amendment as intended.

Migration Act 1958, Compilation No. 145, Registration Date: 11 September 2019 [C2019C00260]

**Subsection 224(6)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***notified detainee*** in subsection 224(6) to the correct alphabetical position.

National Greenhouse and Energy Reporting Act 2007, Compilation No. 20, Registration Date: 11 September 2019 [C2019C00263]

**Paragraph 47(1)(b)**

**Kind of editorial change**

Change to grammar, syntax or the use of conjunctives or disjunctives

**Details of editorial change**

Paragraph 47(1)(b) refers to “a executive officer”.

This compilation was editorially changed to omit “a executive officer” and substitute “an executive officer” to correct the grammatical error.

Radiocommunications Act 1992, Compilation No. 72, Registration Date: 11 September 2019 [C2019C00262]

**Section 5**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***community television broadcasting service*** in section 5 to the correct alphabetical position.

Seas and Submerged Lands Act 1973, Compilation No. 4, Registration Date: 11 September 2019 [C2019C00259]

**Subsections 9(3), 10C(2), 13(2) and 13C(2)**

**Kind of editorial change**

Changes to typeface

**Details of editorial change**

This compilation was editorially changed to update four occurrences of the italicised words *prima facie* to regular font.

**Schedule 1**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

Article 69(3) of the United Nations Convention on the Law of the Sea set out in Schedule 1 refers to “cirumstances” rather than “circumstances”. It is spelt correctly in the original convention.

This compilation was editorially changed to omit “cirumstances” and substitute “circumstances” to correct the typographical error.

Proclamation under Seas and Submerged Lands Act 1973, Compilation No. 2, Registration Date: 4 September 2019 [F2019C00675]

**Sub‑subparagraph (d)(ii)(B) and the Schedule**

**Kind of editorial change**

Changes to the way of referring to or expressing a measurement

**Details of editorial change**

Sub‑subparagraph (d)(ii)(B) and the Schedule contain multiple references to latitude and longitude.

This compilation was editorially changed to omit all references to “South”, “south”, “East” and “east” contained in the expression of latitude and longitude and substitute “S” and “E” respectively to bring these references into line with legislative drafting practice.

This compilation was also editorially changed to update the expression of whole degrees of latitude to 2 numerals and whole degrees of longitude to 3 numerals by inserting “0” at the beginning of each sequence of numbers, as required.

This compilation was also editorially changed to set solid these occurrences of latitude and longitude by omitting the space after the degree symbol and the space after the prime symbol.

Norfolk Island Continued Laws Ordinance 2015, Compilation No. 23, Registration Date: 23 August 2019 [F2019C00666]

**Item 210BA of Schedule 1**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 62 of the *Norfolk Island Legislation Amendment (Fees and Other Matters) Ordinance 2019* provides as follows:

62 Before item 201C of Schedule 1

Insert:

210BA Regulation 3

Repeal the regulation.

The amendment instructs to insert item 210BA before item 201C. However, the amending item was intended to amend the *Pasturage and Enclosure Regulations (Norfolk Island)*.

This compilation was editorially changed to insert item 210BA before item 210C and give effect to the misdescribed amendment as intended.

National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012), Compilation No. 82, Registration Date: 16 August 2019 [F2019C00657]

**Schedule 3, details relevant to Responsible Person code PQ**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 111 of the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2019 (No. 7)* (PB 58 of 2019) provides as follows:

[111] Schedule 3

omit:

|  |  |  |
| --- | --- | --- |
| PQ | PIMP Pty Ltd | 39 114 633 117 |

The words “PIMP Pty Ltd” do not appear in the details relevant to Responsible Person code PQ in Schedule 3. However, the words “PMIP Pty Ltd” do appear.

This compilation was editorially changed to omit the entry for Responsible Person code PQ in Schedule 3 and give effect to the misdescribed amendment as intended.

Australian Crime Commission (National Policing Information Charges) Determination 2016, Compilation No. 1, Registration Date: 15 August 2019 [F2019C00653]

**Subsection 2(1) (table item 1, column 2)**

**Kind of editorial change**

Update to a reference of a law or a provision

**Details of editorial change**

This compilation was editorially changed to update a reference from *Australian Crime Commission Amendment (National Policing Information Charges) Act 2016* to *Australian Crime Commission (National Policing Information Charges) Act 2016* in subsection 2(1) (table item 1, column 2) to reflect the intention for the whole of this instrument to commence at the same time as the *Australian Crime Commission (National Policing Information Charges) Act 2016*.

National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010), Compilation No. 78, Registration Date: 15 August 2019 [F2019C00652]

**Schedule 1, entry for Olmesartan with hydrochlorothiazide**

**Kind of editorial change**

Give effect to the misdescribed amendments as intended

**Details of editorial change**

Schedule 1 items 22 to 24 of the *National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 7)* (PB 65 of 2019) provide as follows:

**[22] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg**

*omit from the column headed “Claimed Price”:*  **7.26** *substitute:*  **7.61**

**[23] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg**

*omit from the column headed “Claimed Price”:*  **12.13** *substitute:*  **12.51**

**[24] Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg**

*omit from the column headed “Claimed Price”:*  **13.55** *substitute:*  **13.90**

The text these items refer to does not appear in the entry for “Olmesartan” in Schedule 1. However, the text referred to in these items does appear in the entry for “Olmesartan with hydrochlorothiazide”.

This compilation was editorially changed to omit “7.26”, “12.13” and “13.55” from the entry for “Olmesartan with hydrochlorothiazide” in Schedule 1 and substitute “7.61”, “12.51” and “13.90” respectively, to give effect to the misdescribed amendments as intended.

Veterans' Entitlements (Provisional Access to Medical Treatment) Determination 2017, Compilation No. 2, Registration Date: 12 August 2019 [F2019C00645]

**Paragraph 9(1)(c)**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

Item 5 of the Schedule to the *Veterans' Entitlements (Provisional Access to Medical Treatment) Amendment Determination No.2 2019* instructs to omit and substitute paragraph 9(1)(c). The substituted paragraph 9(1)(c) refers to “trail”.

This compilation was editorially changed to omit the word “trail” and substitute the word “trial” in paragraph 9(1)(c) to correct the typographical error.

Civil Aviation Safety Regulations 1998, Compilation No. 81, Registration Date: 6 August 2019 [F2019C00626]

**Regulation 142.035**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***recurrent training*** in regulation 142.035 to the correct alphabetical position.

Health Insurance (Health Care Homes) Determination 2017, Compilation No. 1, Registration Date: 2 August 2019 [F2019C00623]

**Section 6 (heading)**

**Kind of editorial change**

Change to spelling

**Details of editorial change**

The heading to section 6 refers to “Limitiation” rather than “Limitation”.

This compilation was editorially changed to omit the word “Limitiation” and substitute the word “Limitation” to correct the spelling.

National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010), Compilation No. 96, Registration Date: 31 July 2019 [F2019C00616]

**Schedule 3, entry for Pasireotide**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 9(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 6)* (PB 48 of 2019) provides as follows:

**[9] Schedule 3, entry for Pasireotide**

**(a)** *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C6330 |  | Acromegaly Grandfathering treatment Patient must have received non PBS treatment with this drug for this condition prior to 1 September 2016. Patient must be aged 18 years or older. In a patient treated with radiotherapy, pasireotide should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pasireotide should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as: 1) Growth hormone (GH) levels of less than 2.5 mcg/L; and 2) normalisation of sex and age adjusted insulin like growth factor 1 (IGF 1) The authority application must be made in writing and must include: a) a completed authority prescription form; and b) a completed Acromegaly PBS Authority Application Supporting Information Form; and c) a signed patient acknowledgment; and d) in a patient who has previously been treated with radiotherapy for this condition, the date of completion of radiotherapy must be provided; and a copy of GH and IGF 1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy must be provided. | Compliance with Written Authority Required procedures |

The text contained in the Circumstances Code C6330 for the entry of Pasireotide in Schedule 3 does not exactly match the text to be omitted as outlined in Schedule 1 paragraph 9(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 6)* (PB 48 of 2019). All the hyphens are missing throughout the entry from the amendment.

This compilation was editorially changed to omit the Circumstances Code C6330 for the entry of Pasireotide in Schedule 3 and give effect to the misdescribed amendment as intended.

**Schedule 3, entry for Pasireotide**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 9(b) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 6)* (PB 48 of 2019) provides as follows:

**(b)** *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C7027 |  | Acromegaly Initial treatment Patient must not have previously received PBS subsidised treatment with this drug for this condition; AND Patient must have a mean growth hormone (GH) level greater than 2.5 micrograms per litre; AND Patient must have an age and sex adjusted insulin like growth factor 1 (IGF 1) level greater than 1.3 times the upper limit of normal (ULN); AND The treatment must be after failure to achieve biochemical control with a maximum indicated dose of either 30 mg octreotide LAR or 120 mg lanreotide ATG every 28 days for 24 weeks; unless contraindicated or not tolerated according to the TGA approved Product Information; AND The treatment must not be given concomitantly with PBS subsidised pegvisomant. Patient must be aged 18 years or older. If treatment with either octreotide or lanreotide is contraindicated according to the relevant TGA approved Product Information, the application must provide details of contraindication. If intolerance to either octreotide or lanreotide treatment developed during the relevant period of use which is of a severity to necessitate withdrawal of the treatment, the application must provide details of the nature and severity of this intolerance. Failure to achieve biochemical control is defined as: 1) Growth hormone level is greater than 2.5 mcg/L; and 2) IGF 1 level is greater than 1.3 times the age and sex adjusted ULN In a patient treated with radiotherapy, pasireotide should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pasireotide should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as: 1) Growth hormone (GH) levels of less than 2.5 mcg/L; and 2) normalisation of sex and age adjusted insulin like growth factor 1 (IGF 1) The authority application must be made in writing and must include: a) a completed authority prescription form; and b) a completed Acromegaly PBS Authority Application Supporting Information Form; and c) a signed patient acknowledgment; and d) in a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy must be provided; and a copy of GH and IGF 1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy must be provided; and e) a recent copy of GH and IGF 1 levels must be provided. | Compliance with Written Authority Required procedures |

The text contained in the Circumstances Code C7027 for the entry of Pasireotide in Schedule 3 does not exactly match the text to be omitted as outlined in Schedule 1 paragraph 9(b) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 6)* (PB 48 of 2019). All the hyphens are missing throughout the entry from the amendment.

This compilation was editorially changed to omit the Circumstances Code C7027 for the entry of Pasireotide in Schedule 3 and give effect to the misdescribed amendment as intended.

**Schedule 3, entry for Pegvisomant**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 paragraph 10(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 6)* (PB 48 of 2019) provides as follows:

**[10] Schedule 3, entry for Pegvisomant**

**(a)** *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C7068 |  | Acromegaly Initial treatment Patient must not have previously received PBS subsidised treatment with this drug for this condition; AND Patient must have an age and sex adjusted insulin like growth factor 1 (IGF 1) concentration greater than 1.3 times upper limit of normal (ULN); AND The treatment must be after failure to achieve biochemical control with a maximum indicated dose of either 30 mg octreotide LAR or 120 mg lanreotide ATG every 28 days for 24 weeks; unless contraindicated or not tolerated according to the TGA approved Product Information; AND The treatment must not be given concomitantly with a PBS subsidised somatostatin analogue. Somatostatin analogues include octreotide, lanreotide and pasireotide Failure to achieve biochemical control after completion of a prior therapy with either octreotide or lanreotide is defined as: 1) Growth hormone level greater than 2.5 mcg/L; and 2) IGF 1 level is greater than 1.3 times the age and sex adjusted ULN If treatment with either octreotide or lanreotide is contraindicated according to the relevant TGA approved Product Information, the application must provide details of contraindication. If intolerance to either octreotide or lanreotide treatment developed during the relevant period of use which is of a severity to necessitate withdrawal of the treatment, the application must provide details of the nature and severity of this intolerance. In a patient treated with radiotherapy, pegvisomant should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pegvisomant should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as normalisation of sex and age adjusted insulin like growth factor 1 (IGF 1). Two completed authority prescriptions should be submitted with the initial application for this drug. One prescription should be for the loading dose of 80 mg for a quantity of 4 vials of 20 mg with no repeats. The second prescription should be for subsequent doses, starting from 10 mg daily, and allowing dose adjustments in increments of 5 mg based on serum IGF 1 levels measured every 4 to 6 weeks in order to maintain the serum IGF 1 level within the age adjusted normal range based on the dosage recommendations in the TGA approved Product Information. The authority application must be made in writing and must include: a) two completed authority prescription forms ; and b) a completed Acromegaly Pegvisomant initial PBS Authority Application Supporting Information Form; and c) in a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy, the date and result of IGF 1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy; and d) a recent result of the IGF 1 level and the date of assessment ; and e) demonstration of failure to achieve biochemical control after completion of a prior therapy with either octreotide or lanreotide No increase in the maximum quantity or number of units may be authorised for the loading dose. | Compliance with Written Authority Required procedures |
|  | C7070 |  | Acromegaly Grandfathering Patient must have received non PBS subsidised treatment with this drug for this condition prior to 1 September 2017; AND The treatment must not be given concomitantly with a PBS subsidised somatostatin analogue; AND Patient must have had a documented age and sex adjusted insulin like factor 1 (IGF 1) concentration greater than 1.3 times upper limit of normal (ULN) prior to commencing non PBS subsidised treatment with this drug. Somatostatin analogues include octreotide, lanreotide and pasireotide In a patient treated with radiotherapy, pegvisomant should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pegvisomant should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as normalisation of sex and age adjusted insulin like growth factor 1 (IGF 1). Treatment must be ceased if IGF 1 level is not lower after 3 months of pegvisomant treatment at the maximum tolerated dose. A patient may qualify for PBS subsidised treatment under this restriction once only. For continuing PBS subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria. The authority application must be made in writing and must include: a) a completed authority prescription form; and b) a completed Acromegaly Pegvisomant Grandfather PBS Authority Application Supporting Information Form; and c) in a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy, the date and result of IGF 1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy; and d) a recent result of the IGF 1 level and the date of assessment. | Compliance with Written Authority Required procedures |

The text contained in the Circumstances Codes C7068 and C7070 for the entry of Pegvisomant in Schedule 3 does not exactly match the text to be omitted as outlined in Schedule 1 paragraph 10(a) of the *National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2019 (No. 6)* (PB 48 of 2019). All the hyphens are missing throughout the entry from the amendment.

This compilation was editorially changed to omit the Circumstances Codes C7068 and C7070 for the entry of Pegvisomant in Schedule 3 and give effect to the misdescribed amendment as intended.

Social Security (Family Law Affected Income Streams) (FaHCSIA) Principles 2011, Compilation No. 1, Registration Date: 30 July 2019 [F2019C00609]

**Part 5 (heading)**

**Kind of editorial change**

Removal of redundant text

**Details of editorial change**

Schedule 1 item 6 of the *Social Security Amendment (Family Law Affected Income Streams) Principles 2019* instructs to insert Parts 5 and 6 after Part 4.

The newly inserted Part 5 heading reads as follows:

Part 5 Income from of asset-tested income streams (lifetime)

This compilation was editorially changed to omit the redundant word “of” from the heading to Part 5.

Business Names Registration Act 2011, Compilation No. 2, Registration Date: 29 July 2019 [C2019C00233]

**Paragraph 8(b) of Schedule 1**

**Kind of editorial change**

Update to a reference of a law or a provision

**Details of editorial change**

This compilation was editorially changed to reflect a change in the way that Northern Territory laws are cited.

Therapeutic Goods (Medical Devices) Regulations 2002, Compilation No. 40, Registration Date: 29 July 2019 [F2019C00603]

**Dictionary**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definitions of ***classification***, ***classification rules***, ***Class I medical device***, ***Class IIa medical device***, ***Class IIb medical device*** and ***Class III medical device*** in the Dictionary to the correct alphabetical positions.

Income Tax Assessment Act 1936, Compilation No. 162, Registration Date: 25 July 2019 [C2019C00228]

**Subsection 6H(6)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***accounts*** in subsection 6H(6) to the correct alphabetical position.

**Subsection 317(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definitions of ***transitional finance share*** and ***transitional finance share dividend*** in subsection 317(1) to the correct alphabetical positions.

A New Tax System (Family Assistance) Act 1999, Compilation No. 96, Registration Date: 24 July 2019 [C2019C00227]

**Subsection 3(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***second income threshold*** in subsection 3(1) to the correct alphabetical position.

AusCheck Regulations 2017, Compilation No. 4, Registration Date: 24 July 2019 [F2019C00590]

**Subsections 16A(2) and (3) and 20B(2) and (3)**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

Subsections 16A(2) and (3) and 20B(2) and (3) refer to “Auscheck” rather than “AusCheck”.

This compilation was editorially changed to omit “Auscheck” and substitute “AusCheck” in subsections 16A(2) and (3) and 20B(2) and (3) to correct the typographical error.

Customs Act 1901, Compilation No. 155, Registration Date: 24 July 2019 [C2019C00226]

**Subsection 4(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***child*** in subsection 4(1) to the correct alphabetical position.

**Schedule I**

**Kind of editorial change**

Change to the way of referring to or expressing a date

**Details of editorial change**

The form in Schedule I refers to a “day of 19 .”

This compilation was editorially changed to omit “day of 19 .” and substitute “*[insert date]*.”in the Schedule I form to bring it in line with legislative drafting practice.

Income Tax (Effective Life of Depreciating Assets) Determination 2015, Compilation No. 4, Registration Date: 24 July 2019 [F2019C00589]

**Table A, industry category MINING (06000 to 10900), sub-category Oil and gas extraction (07000)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 2 of the *Income Tax (Effective Life of Depreciating Assets) Amendment Determination 2019 (No 1)* provides as follows:

**[2] Table A, industry category *MINING (06000 to 10900)*,sub*-*category *Oil and gas extraction (07000)***

*Omit whenever occur*

|  |  |  |  |
| --- | --- | --- | --- |
| Floating production storage and offloading (FPSO) vessels (incorporating mooring systems) | 20 | \*# | 1 Jul 2002 |
| Floating storage and offloading (FSO) vessels (incorporating mooring systems) | 20 | \*# | 1 Jul 2002 |

These table rows only appear once in the table. However, the following table rows appear but refer to “system” rather than “systems”:

|  |  |  |  |
| --- | --- | --- | --- |
| Floating production storage and offloading (FPSO) vessels (incorporating mooring system) | 20 | \*# | 1 Jul 2002 |
| Floating storage and offloading (FSO) vessels (incorporating mooring system) | 20 | \*# | 1 Jul 2002 |

This compilation was editorially changed to omit the following four table rows and give effect to the misdescribed amendment as intended:

|  |  |  |  |
| --- | --- | --- | --- |
| Floating production storage and offloading (FPSO) vessels (incorporating mooring systems) | 20 | \*# | 1 Jul 2002 |
| Floating storage and offloading (FSO) vessels (incorporating mooring systems) | 20 | \*# | 1 Jul 2002 |

|  |  |  |  |
| --- | --- | --- | --- |
| Floating production storage and offloading (FPSO) vessels (incorporating mooring system) | 20 | \*# | 1 Jul 2002 |
| Floating storage and offloading (FSO) vessels (incorporating mooring system) | 20 | \*# | 1 Jul 2002 |

**Table A, industry category FINANCIAL AND INSURANCE SERVICES (62100 to 64200)**

**Kind of editorial change**

Removal of redundant text

**Details of editorial change**

Schedule 1 item 10 of the *Income Tax (Effective Life of Depreciating Assets) Amendment Determination 2019 (No 1)* provides as follows:

**[10] Table A, industry category *FINANCIAL AND INSURANCE SERVICES (62100 TO 64200)***

*Omit*

|  |  |  |  |
| --- | --- | --- | --- |
| Banks: |  |  |  |
| Demountable strongrooms | 100 |  | 1 Jan 2001 |
| Portable safes | 40 |  | 1 Jan 2001 |
| Strongroom doors | 100 |  | 1 Jan 2001 |

*Substitute*

| ***Banking, building society and credit union operations***  ***(62210 to 62230)*** | | | |
| --- | --- | --- | --- |
| **ASSET** | **LIFE (YEARS)** | **REVIEWED** | **DATE OF APPLICATION** |
| Automatic teller machines (ATMs) – see Table B Automatic teller machines (ATMs) |  |  |  |

[not all of substituted text included here]

This action results in two occurrences of the column headings “**ASSET**”, “**LIFE (YEARS)**”, “**REVIEWED**” and “**DATE OF APPLICATION**” in the same table.

This compilation was editorially changed to omit the redundant first occurrence of the column headings “**ASSET**”, “**LIFE (YEARS)**”, “**REVIEWED**” and “**DATE OF APPLICATION**” in Table A, industry category FINANCIAL AND INSURANCE SERVICES (62100 to 64200).

Maritime Transport and Offshore Facilities Security Regulations 2003, Compilation No. 37, Registration Date: 24 July 2019 [F2019C00591]

**Subclause 108(3) of Schedule 2**

**Kind of editorial change**

Updates to cross‑references

**Details of editorial change**

Subclause 108(3) of Schedule 2 refers to “this regulation” (twice occurring).

This compilation was editorially changed to update the cross‑references by omitting the words “this regulation” (twice occurring) and substituting the words “this clause”.

Taxation Administration Act 1953, Compilation No. 163, Registration Date: 23 July 2019 [C2019C00225]

**Subsection 13D(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definitions of ***State tax law*** and ***Territory tax law*** in subsection 13D(1) to the correct alphabetical positions.

National Trade Measurement Regulations 2009, Compilation No. 7, Registration Date: 22 July 2019 [F2019C00581]

**Subregulation 5.2(1) (notes 1 to 4)**

**Kind of editorial change**

Updates to cross-references

**Details of editorial change**

The notes to subregulation 5.2(1) refer to paragraphs (a)(ii), (b)(ii), (c)(iii) and (d)(iii).

This compilation was editorially changed by updating these cross-references from “paragraph” to “subparagraph”.

Health Insurance Act 1973, Compilation No. 109, Registration Date: 19 July 2019 [C2019C00223]

**Subsection 129AADA(3)**

**Kind of editorial change**

Change to grammar, syntax or the use of conjunctives or disjunctives

**Details of editorial change**

Schedule 1 item 9 of the *Health Legislation Amendment (Improved Medicare Compliance and Other Measures) Act 2018* instructs to insert “129ACB(6)” after “subsection 129AAJ(5)” in subsection 129AADA(3).

Subsection 129AADA(3) reads as follows:

(3) However, if an application for review of the decision to claim the amount as a debt is made under subsection 129AAJ(1) or 129ACB(1), the period ends on the day a notice is given under subsection 129AAJ(5) 129ACB(6) notifying the person of the outcome of the review.

This compilation was editorially changed to insert the word “or” after “subsection 129AAJ(5)” to correct the grammatical error.

Therapeutic Goods Regulations 1990, Compilation No. 88, Registration Date: 19 July 2019 [F2019C00575]

**Regulation 2**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***authorised officer*** in regulation 2 to the correct alphabetical position.

**Paragraphs 3(3)(g) and (h)**

**Kind of editorial change**

Updates to references of a law or a provision

**Details of editorial change**

This compilation was editorially changed to reflect a change in the way that Northern Territory laws are cited.

**Schedule 9, clause 4, item 4, paragraphs (d), (e) and (f)**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

Schedule 1 item 21 (table item 156) of the *Therapeutic Goods Legislation Amendment (Fees and Other Measures) Regulations 2019* instructs to omit “4,430” and substitute “4520” in paragraphs (d), (e) and (f) of item 4 of clause 4 of Schedule 9.

This compilation was editorially changed to omit “4520” and substitute “4,520” in paragraphs (d), (e) and (f) of item 4 of clause 4 of Schedule 9 to correct the typographical error.

Migration Regulations 1994, Compilation No. 200, Registration Date: 18 July 2019 [F2019C00567]

**Subparagraph 1124B(2)(a)(vii) of Schedule 1 (table item 3)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 1 item 81 of the *Migration Amendment (Visa Application Charges) Regulations 2019* instructs to omit “$1 795” and substitute “$1 935” in subparagraph 1124B(2)(a)(vii) of Schedule 1 (table item 3).

The amount of “$1 795” does not appear in subparagraph 1124B(2)(a)(vii) of Schedule 1 (table item 3). However, the amount of “1 795” does appear.

This compilation was editorially changed to omit “1 795” and substitute “$1 935” in subparagraph 1124B(2)(a)(vii) of Schedule 1 (table item 3) and give effect to the misdescribed amendment as intended.

AusCheck Regulations 2017, Compilation No. 3, Registration Date: 16 July 2019 [F2019C00554]

**Paragraph 30(2A)(a)**

**Kind of editorial change**

Removal of redundant text

**Details of editorial change**

Schedule 1 item 26 of the *AusCheck Legislation Amendment (Required Information) Regulations 2019* instructs to insert subsections 30(2A), (2B) and (2C) after subsection 30(2).

The newly inserted paragraph 30(2A)(a) reads as follows:

(a) the Secretary makes a request in relation to the application under section subsection 11A(2); and

This compilation was editorially changed to omit the redundant word “section” from paragraph 30(2A)(a).

Banking Act 1959, Compilation No. 55, Registration Date: 16 July 2019 [C2019C00218]

**Subsection 5(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***financial market*** in subsection 5(1) to the correct alphabetical position.

Income Tax Assessment Act 1997, Compilation No. 194, Registration Date: 12 July 2019 [C2019C00212]

**Section 30‑95 (table item 11.2.11 (second occurring))**

**Kind of editorial change**

Renumbering of provisions

**Details of editorial change**

Schedule 4 item 74 of the *Treasury Laws Amendment (2019 Measures No. 1) Act 2019* inserts table item 11.2.11 in the appropriate position in section 30‑95.

Table item 11.2.11 already appears in section 30‑95.

This compilation was editorially changed by renumbering the newly inserted, second occurring table item 11.2.11 to table item 11.2.12.

**Section 30‑315 (table item 23)**

**Kind of editorial change**

Update a cross‑reference

**Details of editorial change**

Schedule 4 item 75 of the *Treasury Laws Amendment (2019 Measures No. 1) Act 2019* repeals and substitutes table item 23 in section 30‑315 which refers to item 11.2.11.

This compilation was editorially changed to update the cross‑reference by omitting the words “item 11.2.11” and substituting the words “item 11.2.12”. This editorial change is consequential upon the editorial change to section 30‑95 (table item 11.2.11 (second occurring)) made in this compilation.

Student Assistance Act 1973, Compilation No. 57, Registration Date: 12 July 2019 [C2019C00213]

**Subsection 3(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***index number*** in subsection 3(1) to the correct alphabetical position.

Social Security Act 1991, Compilation No. 171, Registration Date: 10 July 2019 [C2019C00211]

**Subsection 23(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definitions of ***member of a couple***, ***member of an ordinary couple with different principal homes***, ***members*** and ***Military Rehabilitation and Compensation Act Education and Training Scheme*** in subsection 23(1) to the correct alphabetical positions.

Private Health Insurance (Complying Product) Rules 2015, Compilation No. 21, Registration Date: 8 July 2019 [F2019C00527]

**Subrule 8A(3) (subparagraph (a)(iii) of the definition of *patient contribution*)**

**Kind of editorial change**

Give effect to the misdescribed amendment as intended

**Details of editorial change**

Schedule 2 item 1 of the *Private Health Insurance (Complying Product) Amendment Rules (No. 2) 2019* instructs to repeal and substitute subsection 8A(3) (subparagraph (a)(iii) of the definition of ***patient contribution***).

Subsection 8A(3) does not appear. However, subrule 8A(3) does appear.

This compilation was editorially changed to repeal and substitute subrule 8A(3) (subparagraph (a)(iii) of the definition of ***patient contribution***) and give effect to the misdescribed amendment as intended.

Superannuation (PSSAP) Membership Eligibility (Inclusion) Declaration 2005, Compilation No. 8, Registration Date: 4 July 2019 [F2019C00522]

**Paragraph 12(c) of Schedule 1**

**Kind of editorial change**

Removal of redundant text

**Details of editorial change**

Paragraph 12(c) of Schedule 1 reads as follows:

(c) immediately before becoming so employed was performing duties for **AHPRA** in accordance with the document entitled ‘Memorandum of Understanding between **AHPRA** and the Department of ACT Health regarding the the transition of staff to the National Registration and Accreditation Scheme’ and dated March 2010.

Paragraph 12(c) of Schedule 1 contains two consecutive occurrences of the word “the”.

This compilation was editorially changed to omit the redundant word “the” (fourth occurring) from paragraph 12(c) of Schedule 1.

Superannuation (PSS) Membership Inclusion Declaration 2006, Compilation No. 8, Registration Date: 4 July 2019 [F2019C00521]

**Paragraph 27(c) of Schedule 1**

**Kind of editorial change**

Removal of redundant text

**Details of editorial change**

Paragraph 27(c) of Schedule 1 reads as follows:

(c) immediately before becoming so employed was performing duties for AHPRA in accordance with the document entitled ‘Memorandum of Understanding between AHPRA and the Department of ACT Health regarding the the transition of staff to the National Registration and Accreditation Scheme’ and dated March 2010.

Paragraph 27(c) of Schedule 1 contains two consecutive occurrences of the word “the”.

This compilation was editorially changed to omit the redundant word “the” (fourth occurring) from paragraph 27(c) of Schedule 1.

Bankruptcy Regulations 1996, Compilation No. 28, Registration Date: 3 July 2019 [F2019C00516]

**Subregulation 1.03(1)**

**Kind of editorial change**

Reordering of definitions

**Details of editorial change**

This compilation was editorially changed to move the definition of ***Tobacco Grower Adjustment Assistance Package*** in subregulation 1.03(1) to the correct alphabetical position.

**Item 3 of Schedule 4 (heading)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

The heading to item 3 of Schedule 4 reads as follows:

**3  Section 9 (Taxable value of car fringe benefits—statutory formula**

This compilation was editorially changed to insert a closing bracket after “**formula**” to correct the punctuation.

**Subitem 30.2 of Schedule 4 (paragraph (a) of the definition of *family member* in subsection 136(1))**

**Kind of editorial change**

Change to grammar, syntax or the use of conjunctives or disjunctives

**Details of editorial change**

Subitem 30.2 of Schedule 4 (paragraph (a) of the definition of ***family member*** in subsection 136(1)) refers to “a employee”.

This compilation was editorially changed to omit “a employee” and substitute “an employee” (wherever occurring) to correct the grammatical error.

**Subitem 17.1 of Schedule 7 (paragraph (b) of the definition of *examinable person* in subsection (1AA))**

**Kind of editorial change**

Change to grammar, syntax or the use of conjunctives or disjunctives

**Details of editorial change**

Subitem 17.1 of Schedule 7 (paragraph (b) of the definition of ***examinable person*** in subsection (1AA)) reads as follows:

(b) a person who may be able to give information the relevant person or the examinable affairs of the relevant person; or

This compilation was editorially changed to insert the word “about” before “the relevant person or the examinable affairs” to correct the grammatical error.

**Schedule 8 (table item 26, column headed “Information to be entered in the Index”)**

**Kind of editorial change**

Change to punctuation

**Details of editorial change**

Schedule 8 (table item 26, column headed “Information to be entered in the Index”) reads as follows:

  particulars of bankrupt (if different from particulars in section 188 authority))

This compilation was editorially changed to remove the extra bracket after “authority” to correct the punctuation.

Excise Tariff Act 1921, Compilation No. 52, Registration Date: 1 July 2019 [C2019C00192]

**Paragraph 3(6)(c) (table)**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

The table in paragraph 3(6)(c) contains a reference to “ATSM” rather than “ASTM”.

This compilation was editorially changed to omit “ATSM” and substitute “ASTM” to correct the typographical error.

Protection of the Sea (Powers of Intervention) Act 1981, Compilation No. 13, Registration Date: 1 July 2019 [C2019C00190]

**Paragraph 17(2)(a)**

**Kind of editorial change**

Correct a typographical error

**Details of editorial change**

Paragraph 17(2)(a) refers to “body coporate” rather than “body corporate”.

This compilation was editorially changed to omit “coporate” and substitute “corporate” to correct the typographical error.